About this episode
Professor Peter Nash from the Griffith University in Brisbane, is joined by Dr Mark Russell, a clinical research fellow at the Centre for Rheumatic Diseases, King’s College London to discuss his recent paper 'JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications'.
Get every episode summarized
Each time The IMID Forum publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The IMID Forum
Discussing PsA: Bimekizumab in PsA: Clinical efficacy and updated safety profile
The IMID Forum
Apr 14, 202616:32failed
Author Interview: Professor Helena Marzo-Ortega, March 2026
The IMID Forum
Apr 9, 202637:39failed
Discussing RA: Malignancy risk in patients with RA and the evolution of JAKi pre...
The IMID Forum
Mar 26, 202610:02failed
Discussing axSpA: Symptom duration impact on bimekizumab efficacy and therapeuti...
The IMID Forum
Mar 19, 202633:29failed